Clinical Trials

Yale researchers find phenoxodiol restores sensitivity to chemotherapy in some cancer patients

Published in Proteomics Weekly, April 24th, 2006

Phenoxodiol, an investigational anticancer drug that is being studied by researchers at Yale, has been found to be active and to restore platinum drug sensitivity to some patients who have shown prior resistance to platinum-based chemotherapy agents.

The data were presented at the Annual Meeting on Women's Cancer organized by the Society of Gynecologic Oncology.

The study is designed to test the ability of phenoxodiol to reverse the resistance that develops in most ovarian cancers to standard chemotherapy. The study was conducted at Yale-New Haven Hospital, Conn., U.S., and at the Royal Women's Hospital, Melbourne, Australia.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2006-04-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry